METASTATIC HER2-NEGATIVE BREAST CANCER
Clinical trials for METASTATIC HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo targets rare, Mutation-Rich breast cancer
Disease control OngoingThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 30 people with a rare, advanced form of HER2-negative breast cancer that has many genetic mutations (hypermutated). The goal was to see if this drug pair could shrink or control the cancer. P…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug cocktail aims to delay chemo in metastatic breast cancer
Disease control OngoingThis study tests a combination of three drugs (nivolumab, bicalutamide, and ipilimumab) in 30 people with advanced HER2-negative breast cancer that has spread. The goal is to see if this chemo-free approach can control the disease for at least 24 weeks. Participants must have mea…
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Personalizing chemo: enzyme test may guide capecitabine dosing
Knowledge-focused OngoingThis study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …
Matched conditions: METASTATIC HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC